[{"id":"79eb9129-3b73-42ab-b524-c6f2ef45d1b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05617040","created_at":"2025-02-26T11:21:30.189Z","updated_at":"2025-02-26T11:21:30.189Z","phase":"Phase 1/2","brief_title":"Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer","source_id_and_acronym":"NCT05617040","lead_sponsor":"Barinthus Biotherapeutics","biomarkers":" MSI • CD8 • CD4","pipe":" | ","alterations":" FOLH1 positive","tags":["MSI • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 positive"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 144","initiation":"Initiation: 01/30/2023","start_date":" 01/30/2023","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-10-01"},{"id":"038375f4-2f52-40ca-930c-a5ed704d0f1e","acronym":"3TMPO","url":"https://clinicaltrials.gov/study/NCT04000776","created_at":"2021-09-21T22:54:25.528Z","updated_at":"2025-02-25T16:09:16.795Z","phase":"","brief_title":"3TMPO (Triple-Tracer Strategy Against Metastatic Prostate Cancer","source_id_and_acronym":"NCT04000776 - 3TMPO","lead_sponsor":"Université de Sherbrooke","biomarkers":" SYP","pipe":" | ","alterations":" FOLH1 positive","tags":["SYP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 positive"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 12/16/2019","start_date":" 12/16/2019","primary_txt":" Primary completion: 03/30/2023","primary_completion_date":" 03/30/2023","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2023-08-28"},{"id":"64747c1c-720a-487f-8d34-96ace937605a","acronym":"PRIMARY2","url":"https://clinicaltrials.gov/study/NCT05154162","created_at":"2021-12-10T23:53:39.221Z","updated_at":"2024-07-02T16:35:41.590Z","phase":"Phase 3","brief_title":"PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI","source_id_and_acronym":"NCT05154162 - PRIMARY2","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation • FOLH1 positive","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation • FOLH1 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 660","initiation":"Initiation: 03/02/2022","start_date":" 03/02/2022","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2023-07-28"},{"id":"39ce37ab-f38e-4a84-88f1-c50c87b449a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05596851","created_at":"2022-10-27T15:58:37.446Z","updated_at":"2024-07-02T16:36:01.719Z","phase":"","brief_title":"Radio-guided Surgery With DROP-IN Beta Probe for 68Ga-PSMA, in High-risk Prostate Cancer Patients Eligible for Robotic-assisted Radical Prostatectomy.","source_id_and_acronym":"NCT05596851","lead_sponsor":"European Institute of Oncology","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression • FOLH1 positive","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression • FOLH1 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 03/21/2022","start_date":" 03/21/2022","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-10-27"}]